Emmaus Life Sciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Revenues, net - Summarizes Revenues from Each of our Customers Accounted for 10% or More of Net Revenues (Details)

Revenues, net - Summarizes Revenues from Each of our Customers Accounted for 10% or More of Net Revenues (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Customer A [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	13.00%	20.00%
Customer B [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	14.00%	10.00%
Customer C [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	16.00%	30.00%
Customer D [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	19.00%	15.00%
Customer E [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	26.00%	1.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References + Details